Primary sclerosing cholangitis in children: A long-term follow-up study

Authors

  • Ariel E. Feldstein,

    1. Division of Gastroenterology and Hepatology, Department of Pediatric and Adolescent Medicine, Mayo Medical School, Clinic and Foundation, Rochester, MN
    Search for more papers by this author
  • Jean Perrault,

    1. Division of Gastroenterology and Hepatology, Department of Pediatric and Adolescent Medicine, Mayo Medical School, Clinic and Foundation, Rochester, MN
    Search for more papers by this author
  • Mounif El-Youssif,

    1. Division of Gastroenterology and Hepatology, Department of Pediatric and Adolescent Medicine, Mayo Medical School, Clinic and Foundation, Rochester, MN
    Search for more papers by this author
  • Keith D. Lindor,

    1. Department of Internal Medicine, Mayo Medical School, Clinic and Foundation, Rochester, MN
    Search for more papers by this author
  • Deborah K. Freese,

    1. Division of Gastroenterology and Hepatology, Department of Pediatric and Adolescent Medicine, Mayo Medical School, Clinic and Foundation, Rochester, MN
    Search for more papers by this author
  • Paul Angulo M.D.

    Associate Professor of Medicine, Corresponding author
    1. Department of Internal Medicine, Mayo Medical School, Clinic and Foundation, Rochester, MN
    • Division of Gastroenterology and Hepatology, Mayo Medical School, Clinic and Foundation, 200 First St. SW, Rochester, MN 55905. fax: 507-266-4531
    Search for more papers by this author

Abstract

Primary sclerosing cholangitis (PSC) is increasingly diagnosed in children and adolescents, but its long-term prognosis remains uncertain. The aim of this longitudinal, cohort study was to determine the long-term outcome of children with PSC. Fifty-two children with cholangiography-proven PSC (34 boys and 18 girls; mean age 13.8 ± 4.2 years; range, 1.5-19.6 years) who were seen at our institution over a 20-year period were followed-up for up to 16.7 years. Two thirds presented with symptoms and/or signs of PSC and 81% had concomitant inflammatory bowel disease (IBD). Twenty-five percent had total alkaline phosphatase activity within the normal range for the age group, but all of them had elevated γ-glutamyl transpeptidase levels. Autoimmune hepatitis overlapping with PSC was present in 35% of children. A positive but transient clinical and/or biochemical response occurred under therapy with ursodeoxycholic acid, alone or in combination with immunosuppressive medications. During follow-up, 11 children underwent liver transplantation for end-stage PSC and 1 child died. The median (50%) survival free of liver transplantation was 12.7 years. Compared with an age- and gender-matched U.S. population, survival was significantly shorter in children with PSC (P < .001). In a Cox regression model, lower platelet count, splenomegaly, and older age were associated with shorter survival. Presence of autoimmune hepatitis overlapping with PSC (P = .2) or medical therapy (P = .2) did not affect survival. In conclusion, PSC significantly decreases survival in this child population. Although pharmacologic therapy may improve symptoms and liver test results initially, it does not seem to impact the long-term outcome.

Ancillary